
    
      This is a phase 2, multi-center, randomized, double-blind, vehicle-controlled, ascending dose
      study to assess safety, tolerability and efficacy of a topical nitric oxide releasing
      compound in subjects with external genital and perianal warts. Eligible subjects will be
      treated with a topical gel (active or vehicle) for up to 12 weeks.
    
  